Press Enter to search · ESC to close

Crypto

Grand Pharma’s Migraine Prevention TCM Drug GPN01020 Doses First Patient in Phase II Trial

Grand Pharma has completed enrollment of the first patient in a Phase II clinical trial in China for GPN01020, a Class 1.1 traditional Chinese medicine innovative drug for migraine prevention. The company called the milestone a key step for its otolaryngology Chinese patent medicine portfolio, marking the transition of the hospital-formulation-derived drug from long-term clinical experience into evidence-based validation.

Share

Related News

Cointime share card
Long-press the image to save or share
Pitch us Community Feedback